Experimental drugs to cure Alzheimer’s disease from Roche Holding AG and Eli Lilly & Co.(NYSE:LLY) have been chosen for a high-profile medical trial to test if it is possible to stop the disease from developing in at-risk patients.
Th trial is expected to begin sometime next year. It is going to enroll 160 patients internationally with inherited gene mutations that usually result in Alzheimer’s symptoms when they are in their 30s. Washington University said this while announcing the selection of drugs on Wednesday.
Studies over drugs over the past decade have tried and failed to slow progression of Alzheimer’s among patients, who are undergoing dementia. There is hope of some triumph in arresting symptoms in patients, who are so highly inclined to develop the ailment. It will show the way to stop Alzheimer’s in a much wider population.
A neurologist from Washington University of Medicine, Dr. Randall Bateman said that the team is going to work on three different drugs with three different means of action in order to find out the best method.
Bateman said over a telephonic interview that half the patients in the trial do not have any symptoms when the study had started. The rest will have very minor symptoms.
A neurologist at New York University Langone Medical Center, Dr. James Galvin said that such a prevention trial that involves people at high hereditary risk of Alzheimer’s disease would need comparatively few patients and could generate results within a few years.
Gavin said that every family has a genetic mutation with a definite age of inception of ailment, so people can start giving the drug a certain number of years before the predicted onset.
Around 5 million people in the US and 36 million internationally are believed to have Alzheimer’s, which happens to be a common type of dementia.